Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.

Bulletin of mathematical biology - 1 Aug 2012

Rong Libin, Ribeiro Ruy M, Perelson Alan S

Abstract excerpt

Telaprevir, a novel hepatitis C virus (HCV) NS3-4A serine protease inhibitor, has demonstrated substantial antiviral activity in patients infected with HCV. However, drug-resistant HCV variants were detected in vivo at relatively high frequency a few days after drug administration. Here we use a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Drug Resistance, Viral
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hepatocytes

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 22639338
DOI: 10.1007/s11538-012-9736-y
PMCID: PMC3400267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22639338-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.PMID 22639338Read ↗

Rapid emergence of protease inhibitor resistance in hepatitis C virus.Semantic proximity Read ↗

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.Semantic proximity Read ↗

The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations.Semantic proximity Read ↗

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistenceSemantic proximity Read ↗

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.Semantic proximity Read ↗

Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications.Semantic proximity Read ↗

A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.Semantic proximity Read ↗

Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach.Semantic proximity Read ↗

Rational design and adaptive management of combination therapies for Hepatitis C virus infectionSemantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics.Semantic proximity Read ↗

Nested model reveals potential amplification of an HIV epidemic due to drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.